Overview of Lassie

Quick Facts

Property	Description
Active ingredient	Pyrantel (as Pamoate or Embonate salt)
Form	Oral suspension, tablets
Pharmacological class	Anthelmintic / Antiparasitic agent
Common use	Treatment of intestinal worm infections
Origin	Synthetic pyrimidine derivative

What Type of Medicine is Lassie (Pyrantel)?

Lassie is fundamentally defined as a synthetic antiparasitic agent that belongs to the anthelmintic pharmacological group, established for the general purpose of clearing intestinal parasites. The drug’s core active component, Pyrantel, is a molecule that is clinically recognized for its efficacy against specific helminth infections. This recognition underscores its value as a specialized tool in public health initiatives. The brand Lassie often features specific formulations, such as palatable oral suspension or chewable tablets, designed to facilitate simplified administration, particularly for the target patient group, such as children aged two years and older, dealing with conditions like pinworm infection.

Lassie's Composition, Form, and Origin

The medicinal composition of Lassie is centered on the active ingredient Pyrantel, supplied primarily as the salts Pyrantel Pamoate or Pyrantel Embonate. Pyrantel is a synthetic pyrimidine derivative, meaning its source is chemical synthesis rather than natural extraction. As a single-active-ingredient product, it is administered through the oral route of administration and is available in high-level dosage forms including oral suspension and tablet presentations. The compound's documented therapeutic effectiveness is well-established. The formulation is designed for minimal systemic absorption, ensuring the primary antiparasitic effect is localized directly in the intestine, which minimizes systemic exposure.

What side effects are possible with Lassie?

Possible Side Effects and Safety Information

The officially documented safety profile for Pyrantel Pamoate (Lassie) primarily involves effects categorized as sometimes occurring, focusing mainly on the gastrointestinal and nervous systems. This aligns with its localized action and minimal systemic absorption, as noted in regulatory labeling.

Adverse Reactions and System-Organ Classes

The most frequently cited adverse reactions in government regulatory documents fall into the following System-Organ Classes (SOCs):

Gastrointestinal Disorders: Effects documented as sometimes occurring include abdominal cramps, nausea, vomiting, and diarrhea.
Nervous System Disorders: Reactions in this class include headache and dizziness. Less frequently documented effects like drowsiness and insomnia have also been noted.
Hepatobiliary Disorders: There is a documented potential for transient elevation of liver function tests (LFTs).

Serious Safety Considerations

Official safety documents indicate that serious concerns relate to hypersensitivity reactions (allergic reactions) and the effects of overdose. Signs of a systemic reaction, such as swelling or difficulty breathing, define the more clinically significant safety events.

Population-Specific Safety Constraints

The regulatory profile outlines specific limitations on use based on patient characteristics:

Children Under 2 Years Old: Safety and efficacy are not established for this age group; use is advised only under professional direction.
Hepatic Impairment: Caution is advised, and professional direction is required for use in individuals with pre-existing liver disease due to the potential for effects on the liver.
Pregnancy: The drug is advised for use only when clearly needed and under the guidance of a medical professional.

Official labeling also lists known hypersensitivity to the drug and intestinal obstruction as high-level safety constraints for administration.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented signs of overexposure and the mandatory emergency actions as stated in government regulatory labeling.

Feature	Official Regulatory Statement
Documented Overdose Manifestations	Symptoms are typically mild and transient, involving gastrointestinal disturbance (nausea, vomiting, diarrhea) and Central Nervous System (CNS) effects (headache, dizziness, drowsiness). Potential for transient elevation of liver enzyme levels is also documented.
Physiological Systems Affected	Gastrointestinal system and Central Nervous System.
Emergency-Response Statements	No specific antidote is known for overexposure. Treatment is officially described as symptomatic and supportive treatment.
When Immediate Medical Help is Required	Seek immediate medical attention or contact a certified Poison Control Center immediately for advice regarding any suspected overexposure.

Official Overdose Statements:

Overdose manifestations are officially documented as mild and transient and primarily affect the gastrointestinal system and the CNS.
Any suspected overexposure requires immediately seeking medical attention and contacting a Poison Control Center.
No specific antidote is known for Pyrantel, and intervention is officially described as symptomatic and supportive treatment.

The regulatory documentation defines the overdose profile by its typically mild and transient clinical presentation and low systemic absorption. Regardless of this low-risk profile, government labeling mandates that immediate medical care must be sought for any suspected overdose event. The officially described management is strictly supportive, as a specific pharmacological antidote is not listed in the prescribing information.

Therapeutic Uses of Lassie

What Lassie treats: main uses and benefits

Lassie is a medication belonging to the class of drugs known as Angiotensin-Converting Enzyme (ACE) inhibitors. Its role may assist with reducing blood pressure and is relevant for easing the physiological strain on the heart, providing support across therapeutic domains where additional symptomatic support is needed.

Lassie is commonly used to help with symptoms related to heightened physiological activity, specifically in conditions characterized by periods of heightened symptoms like high blood pressure (hypertension), heart failure, and may be part of symptomatic management following an acute myocardial infarction. It is considered relevant in conditions involving episodic or fluctuating manifestations and may be applied in clinical settings that involve acute or unstable symptom patterns. By addressing the overall symptom load, it supports patients during episodes of heightened discomfort and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Supports in managing Symptoms that create noticeable physiological strain

Regulatory References

NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Lassie? — Official Regulatory Information

The eligibility profile for Lassie is defined by mandatory restrictions and absolute contraindications established in regulatory labeling. Use is only permitted in patients who do not possess any of the documented exclusions below.

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Patients with known hypersensitivity to the active substance or to any of the excipients in the formulation.
Physiological Status	Use is contraindicated during pregnancy and lactation.

Restricted and Non-Recommended Populations

Classification	Population/Condition
Age-Related Rule	Use is not established and therefore not recommended in the pediatric population (patients under 18 years of age).
Condition-Specific	Use is not recommended in patients presenting with severe impairment of hepatic or renal function.

These official statements structure the approved patient population by defining high-risk groups for whom the medicine is strictly prohibited. The regulatory documents explicitly exclude those with known allergies to the product, women who are pregnant or breastfeeding, and patients with severe organ dysfunction, reflecting the established eligibility and non-eligibility boundaries.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Lassie (Pyrantel) as established in government regulatory prescribing information.

Interaction scope

Element	Official Regulatory Information for Lassie (Pyrantel)
Medicinal product categories with documented interactions:	Anthelmintic agents; Xanthine derivatives.
Specific interacting medicines (if explicitly listed):	Piperazine; Theophylline.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic antagonism; Unknown mechanism resulting in exposure modification.
Interaction-related restrictions:	Avoid co-administration with Piperazine due to antagonistic effects.

Interaction classifications (high-level)

Element	Official Regulatory Information for Lassie (Pyrantel)
Interaction severity classification:	Formal Combination Prohibition (for Piperazine); Clinically Significant Interaction (for Theophylline exposure increase).
Interaction-context constraints:	Administration is not restricted by co-ingestion with food or drinks.

Official interaction statements

Regulatory documentation confirms that co-administration with the anthelmintic agent Piperazine is formally documented as a combination that must be avoided. This restriction is based on a pharmacodynamic antagonism where the two medicines counteract each other's effects. Separately, co-administration may result in increased plasma concentrations of Theophylline. Furthermore, official regulatory information confirms that administration is not restricted by meals, milk, or fruit juice, as no known interactions with food or drinks are formally documented.

Mechanism of Action

Selective Neuromuscular Targeting and Activation

Pyrantel functions as a selective agonist at specific nicotinic acetylcholine receptors (nAChRs) found on the muscle cells of susceptible parasitic worms (nematodes), causing their continuous activation. This direct, targeted interaction forces the worm's muscle membranes into a state of sustained depolarization, initiating the rapid physiological chain of events.

Mechanism of Spastic Paralysis

The sustained depolarization triggered by Pyrantel results in a depolarizing neuromuscular blockade, leading to a complete and irreversible state of spastic (tetanic) paralysis of the worm's body. The mechanism results in the incapacitation of susceptible parasites. The rapid depolarizing muscle blockade at the target site removes the force generated by the worms needed to maintain attachment to the intestinal wall or for active movement through the gut.

Localized Action and Elimination Cascade

The mechanism is intrinsically limited to the intestinal lumen, where high concentrations of the drug are achieved directly at the parasite's location. The resulting expulsion cascade relies on the host's natural gut motility to passively sweep the paralyzed organisms out of the body, confirming the mechanism's strictly localized physiological effect. This action facilitates the rapid physiological elimination of the incapacitated parasites from the gastrointestinal system.

Dosage and Administration Information

Pyrantel (Lassie) is an anthelmintic medication administered exclusively via the oral route as a standardized, short-term course to treat specific intestinal parasitic infections. Its use is defined by a precise, weight-based single-dose regimen that addresses the logistics of administration and the necessity of preventing re-infection.

Dosing and Administration Protocol

The usage of Pyrantel is based on a high-level weight-based calculation and a controlled frequency pattern.

Instruction Entity	Standard Requirement
Route of Administration	Oral route only.
Dosing Schedule	Single dose of 11 mg of Pyrantel base per kilogram of body weight (11 mg/kg), with a total dose not exceeding 1 gram.
Frequency Pattern	A single oral dose is the standard treatment, typically repeated in 2 to 3 weeks for pinworm infection to complete the two-course regimen.
Administration Timing	May be taken with or without food (including milk or fruit juice).
Preparation	Tablets should be chewed thoroughly or crushed; suspensions must be shaken well before measurement.

Contextual Usage Principles

The successful use of Pyrantel often depends on adherence to practical procedural conditions. The medication requires no pre-treatment fasting or post-treatment purging. For clinical efficacy against certain infections like pinworm, it is noted that the entire household or group should be treated simultaneously, defining the context of use as a critical step in preventing immediate re-exposure and re-infection. The dosage is consistent across adults and children 2 years of age and older, maintaining the weight-based principle across approved age groups. This structured approach defines the comprehensive treatment strategy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lassie (Pyrantel)

Evidence for Pinworm and Roundworm Infections

Research has explored the use of Lassie for pinworm (Enterobius vermicularis) and roundworm (Ascaris lumbricoides). For these uses, short-term Randomized Controlled Trials (RCTs) and Systematic Reviews have been used in research exploring how to achieve parasitic clearance. Studies monitored high rates of parasitic clearance measurements for roundworm. For pinworm, studies describe that a repeat dose was often part of the treatment protocol evaluated. In both cases, the follow-up durations were limited, with most measurements taken within a few weeks.

Evidence for Hookworm and Whipworm Infections

Lassie was also evaluated in comparative clinical trials for hookworm infection (Necator americanus and Ancylostoma duodenale). Studies describe that the parasitic clearance measurements were associated with greater variability when compared to other parasitic outcomes monitored in the research. Findings were mixed for this use.

The research base for Lassie for whipworm infection (Trichuris trichiura) evidence quality varies compared to other indications. The limited evidence for this condition data show patterns related to a lower measurement of parasitic clearance, and studies found measurements were similar to those observed in the placebo or control groups.

Research Gaps and Limitations

The research primarily examined only short-term parasitic clearance metrics. Consequently, long-term effects are not fully established, and there is limited information regarding the durability of the initial clearance or recurrence rates. Data for certain groups remain insufficient; research has predominantly included school-aged children, and evidence is limited for older adults, the severely immunocompromised, or pregnant populations. The research evidence highlights what is known—and what is still uncertain—about the long-term functional outcomes of clearance.

Key Studies & References

Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Lassie (FAQ)

Q: Is Lassie the same kind of medicine as [similar drug name]?

A: The active ingredient in Lassie, Pyrantel Pamoate, belongs to the anthelmintic pharmacological class. This means it is one type of medicine used specifically to treat infections caused by parasitic worms. This classification is shared by other medicines used for similar, though not always identical, purposes.

Q: How quickly does Lassie usually start working?

A: The drug is intended to cause paralysis quickly through its localized mechanism of action. Because the drug is minimally absorbed into the bloodstream, a high concentration is achieved directly at the site of infection.

Q: What happens if I forget to take Lassie?

A: Official instructions for this medicine, which is typically a short-term or single-dose treatment, state that if a dose is missed, it can typically be taken as soon as it is remembered.

Q: What should I do if I think I'm having a side effect from Lassie?

A: If signs of a serious allergic reaction are experienced—such as sudden swelling of the face, tongue, or throat, severe dizziness, or trouble breathing—these symptoms are defined in safety documents as requiring immediate emergency medical attention.

Q: Can Lassie be taken with common over-the-counter pain relievers?

A: Regulatory summaries do not list any severe, serious, or moderate interactions with common over-the-counter pain relievers. However, official guidance recommends sharing a list of all medicines you are taking, including non-prescription products.

Q: Does Lassie interact with any vitamins or supplements?

A: Official interaction summaries focus on medicinal products and specific drugs, and do not explicitly document interactions with common vitamins or supplements. As a general precaution, regulatory materials recommend sharing a list of all supplements with a healthcare provider.

Q: Why is Lassie sometimes prescribed over other treatment options?

A: The active ingredient in Lassie, Pyrantel, is internationally recognized and included on the World Health Organization's List of Essential Medicines. This designation recognizes its therapeutic importance for a basic health system.

Q: What are the main differences between Lassie and a generic version of the drug?

A: The active component in both the brand-name and generic forms is Pyrantel Pamoate. The main differences, according to regulatory documents, often relate to specific dosage forms, such as the availability of palatable oral suspensions or chewable tablets in certain brand formulations.

Q: Does Lassie affect driving ability in most people?

A: Regulatory warnings state that this medicine may cause dizziness or drowsiness. Due to these possible effects, caution is advised before engaging in activities that require mental alertness, such as driving or operating machinery.

Q: What happens when I stop taking Lassie?

A: Lassie is prescribed as a short-term, single-dose course or a brief, two-course regimen. Due to this intended short duration of use, official documents do not list established discontinuation procedures or withdrawal symptoms.

Q: Are there any long-term effects associated with using Lassie?

A: The medication is primarily designed for short-term use, achieving localized action within the intestinal tract with minimal systemic absorption. Research reviews indicate that long-term effects are not fully established, and data on the durability of clearance over extended periods are limited.

Q: Can older adults use Lassie without special precautions?

A: Official regulatory information specifies that no dedicated studies have compared the use of this drug in older adults (the elderly) versus other age groups. Any use in this population is best discussed with a healthcare professional to determine appropriateness.

Q: What is the chance of having a serious allergic reaction to Lassie?

A: Official safety documents confirm the existence of the risk of a serious allergic reaction, also known as hypersensitivity. However, the precise statistical chance or frequency rate is not typically provided in the patient-facing regulatory materials.

Q: Is Lassie considered a controlled substance?

A: The active ingredient, Pyrantel Pamoate, is classified as an anthelmintic agent. It is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA), indicating it does not carry a regulatory risk of abuse or misuse.

Q: How does the time of day I take Lassie relate to its effectiveness?

A: The regulatory administration instructions confirm that the medication can be taken at any time of day and with or without food. Official guidance does not suggest that its effectiveness is dependent on a specific time (e.g., morning or evening).

Q: Does Lassie interfere with common lab tests?

A: Official regulatory documentation mentions the potential for a transient elevation of liver function tests (LFTs) as a documented adverse effect. No other common interferences with lab tests are generally noted.

Q: Is it normal to feel a change in mood while on Lassie?

A: Documented nervous system side effects include specific reactions like headache, dizziness, drowsiness, insomnia, and irritability. Generalized 'changes in mood' are not explicitly listed in the regulatory side effect categories beyond these specific reactions.

Q: Where can I find the official prescribing information for Lassie?

A: The official prescribing information, or Summary of Product Characteristics, is made publicly available by government health authorities. Key sources include the U.S. FDA (DailyMed) and the National Institutes of Health (NIH) MedlinePlus.

Q: What is the half-life of Lassie?

A: The drug is designed to act directly in the intestine with only minimal absorption into the bloodstream. The clinical relevance of its half-life (the time it takes for half the drug to be eliminated from the body) is low for the patient, as its action is primarily localized where the parasites are.

Q: Are there any specific lifestyle restrictions while using Lassie?

A: Regulatory documents specify that to prevent re-infection, simultaneous treatment of all close contacts, such as household members, may be required for certain infections.

Q: Is Lassie known to cause dependency?

A: As an anthelmintic medicine, the drug is not classified as a controlled substance by major regulatory bodies. Official documentation does not list any risk of physical or psychological dependency associated with its use.

Q: Do you need to have a special test before starting Lassie?

A: Regulatory warnings advise caution for use in patients with a history of liver disease or anemia. Warnings indicate that a healthcare provider may request tests to check for underlying conditions such as liver disease or anemia before treatment begins.

Q: Can I drink alcohol while taking Lassie?

A: Official warnings advise that alcohol may increase documented side effects of Lassie, such as dizziness or drowsiness. Due to this potential, regulatory warnings suggest limiting the consumption of alcoholic beverages during treatment.

Q: What should I do if I suspect an overdose of Lassie?

A: If an overdose is suspected, official safety instructions state to contact a Poison Control Center or seek emergency medical services immediately. This is due to the potential for severe gastrointestinal and nervous system effects.

Q: Do I need to take Lassie at the exact same time every day?

A: Lassie is prescribed as a single-dose or a short-course regimen, not as a daily medicine. Given this, the requirement for precise, daily timing is not applicable as it is for daily maintenance medications.

Q: What is the duration of the effect of one dose of Lassie?

A: The duration of one dose's effect is primarily linked to the time it takes for the paralysis of the worms to occur and for the host's natural bowel movement to expel the incapacitated parasites from the body. The effect is intended to last long enough to complete this elimination cascade.

How should Lassie be stored and disposed of?

How to Store and Dispose of Lassie (Pyrantel)

Official regulatory guidelines define specific conditions for storing and discarding Pyrantel to maintain its stability and ensure safety.

Storage Requirement	Official Condition
Temperature	Store at controlled room temperature, generally between 20 C and 25 C (68 F to 77 F).
Protection	Keep the container tightly closed and protect from moisture and excessive heat. The oral suspension form must not be frozen.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be taken to an official drug take-back program when possible. Regulatory documentation restricts pouring the medicine down a toilet or sink. If a take-back program is unavailable, mix the product with an undesirable substance (e.g., dirt) and seal it before placing in the household trash.

Lassie